TLC-6740

TLC-6740 is a novel, oral, liver-targeted small molecule mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including type 2 diabetes and nonalcoholic steatohepatitis (NASH). It acts by uncoupling mitochondrial oxidative phosphorylation specifically in hepatocytes, thereby increasing hepatic energy expenditure. This mechanism leads to weight loss, improved insulin sensitivity, reductions in plasma lipids (including LDL cholesterol), and improvements in glucose tolerance. The drug is designed to achieve high concentrations in the liver with minimal systemic exposure (>40x liver/plasma ratio), which enhances safety by reducing risks associated with systemic mitochondrial uncoupling. Preclinical studies have shown dose-dependent reductions in body weight and improvements in metabolic parameters; Phase 1 clinical trials have demonstrated favorable safety/tolerability profiles and pharmacodynamic effects consistent with increased energy expenditure[1][2][4][5].

Other names

TLC 6740TLC6740TLC-6740